Money and murder: the dark side of the Asilomar meeting on recombinant DNA
By Matthew Cobb,
Nature
| 02. 17. 2025
On 24 February 1975, some 150 people met at the Asilomar Conference Grounds near Monterey on the Californian coast. They were mostly scientists from the United States, together with representatives of various companies and government agencies, and 16 journalists. Their subject was the new technology of recombinant DNA — molecules created in a laboratory by stitching together genetic material from different organisms. Researchers were excited by the possibilities for discoveries, and the potential of the technique to produce drugs, for example using specially engineered bacteria to make insulin. But they were also terrified that they might inadvertently create diseases that could infect lab workers and the wider community.
By the end of the meeting, its participants had agreed to adopt biosafety protocols that are still in force in the United States, and which have hugely influenced similar regulations worldwide. The meeting has become known simply as Asilomar, a byword for how a scientific community came together to forge consensus on a thorny topic. It is often held up as an example of how science can self-regulate without the involvement of...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...